Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TRI, FVT

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial


ROCKVILLE, Md., Feb. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy. Primary investigator Aravindhan Veerapandiyan, M.D. will join the webcast and be available for Q&A.

Webcast details
Title: Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202 
Date/Time: Tuesday, March 5, 2024, at 8:30 a.m. EST
Access: The live webcast can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

Muscular Dystrophy Association Clinical & Scientific Conference presentation details
Title: RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: Interim clinical data
Session: Clinical Trial Updates
Date/Time: Wednesday, March 6, 2024, 12:00 p.m. EST
Presenter: Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital

The presentation will be available in the Publications section of REGENXBIO's website.

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
[email protected] 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
[email protected]

(PRNewsfoto/REGENXBIO Inc.)

 

SOURCE REGENXBIO Inc.


These press releases may also interest you

at 06:35
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in fireside chats at...

at 06:30
10 Fitness Introduces Gated Amenities for Enhanced Member Experience and Unmatched Safety
10 Fitness is taking the member experience to new heights with the introduction of gated amenities, ensuring unparalleled access control and safety within its clubs. This move sets a new industry standard, distinguishing 10 Fitness from traditional...

at 06:10
Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Next Generation Drug Conjugates Market ? By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense...

at 06:07
Seed Health Launches VS-01, A First-of-its Kind Vaginal Microbiome Innovation to Redefine Vaginal Care
An optimal vaginal microbiome is a key driver of gynecological, urogenital, and reproductive health  VS-01tm is a multi-strain probiotic and prebiotic clinically validated to establish an optimal vaginal microbiome and sustain regulated vaginal pH...

at 06:05
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of...

at 06:05
Ellodi Pharmaceuticals Announces FLUTE-2 Data to be Presented at DDW 2024 with APT-1011 in Patients with Eosinophilic Esophagitis
Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, today announced an oral presentation by Professor Evan Dellon M.D., M.P.H, at the Digestive Disease Week (DDW) 2024 Annual Scientific Meeting. The presentation will...

More news about Health...


News published on and distributed by: